# Gritstone bio

Source: https://onco.cc/companies/gritstone/  
OnCo record `gritstone` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Neoantigen-vaccine pioneer (GRANITE, SLATE) that ran out of money and filed for bankruptcy in October 2024; a cautionary tale for the personalised-vaccine field.

## Summary

Gritstone's GRANITE individualised neoantigen vaccine (adenoviral prime, samRNA boost) showed a molecular-response signal in a phase 2/3 colorectal cancer maintenance trial but not enough to fund completion. Chapter 11 filing 10 October 2024; assets sold at auction (Seattle Project Corp. and others) for about $21M in December 2024.

## Fields

- Kind: Company
- Status: withdrawn
- Last checked: 2026-09-04
- Tags: failure
- HQ: Emeryville, CA
- Type: biotech
- Website: https://www.gritstonebio.com

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Gritstone_bio
- Bankruptcy and asset sale: https://www.nasdaq.com/articles/gritstone-bio-files-bankruptcy-and-auctions-assets

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Off-the-shelf cancer vaccines](https://onco.cc/technologies/shared-antigen-vaccine/), [Personalised neoantigen (mRNA) vaccines](https://onco.cc/technologies/neoantigen-mrna-vaccine/)
- drugs: [GRT-C901](https://onco.cc/drugs/grt-c901/), [GRT-R902](https://onco.cc/drugs/grt-r902/)

---
JSON: https://onco.cc/api/v1/entities/gritstone.json